Patients with refractory severe aplastic anemia (SAA) who lack a matched sibling or unrelated donor need new therapeutic approaches. Hematopoietic SCT (HSCT) using mismatched or haploidentical related donors has been used in the past, but was associated with a significant risk of GVHD and mortality. Recently, the use of post-transplant cyclophosphamide (Cy) has been shown to be an effective strategy to prevent GVHD in recipients of haploidentical HSCT, but the majority of reports have focused on patients with hematology malignancies. We describe the outcome of 16 patients who underwent haploidentical transplantation using a reduced-intensity conditioning regimen with post-transplant Cy. Stem cell sources were BM (N = 13) or PBSCs (N = 3). The rate of neutrophil engraftment was 94% and of platelet engraftment was 75%. Two patients had secondary graft failure and were successfully salvaged with another transplant. Three patients developed acute GVHD being grades 2-4 in two. Five patients have died and the 1-year OS was 67.1% (95% confidence interval: 36.5-86.4%). In our small series, the use of a reduced-intensity conditioning with post-transplant Cy in haploidentical BMT was associated with high rates of engraftment and low risk of GVHD in patients with relapsed/refractory SAA. 
INTRODUCTION
Patients with refractory severe aplastic anemia (SAA) who lack a histocompatible related or unrelated donor are at risk of developing complications from persistent pancytopenia and clonal evolution to secondary myelodysplastic syndrome and acute myeloid leukemia. [1] [2] [3] [4] [5] Current therapeutic strategies for these patients include a higher risk hematopoietic stem cell transplantation (HSCT) from mismatched donors, a second course of immunosuppression, androgens, and more recently, the TPO receptor agonist eltrombopag recently approved in this setting. 3, [6] [7] [8] [9] [10] Higher risk HSCT for those who lack a histocompatible donor often include umbilical cord blood and haploidentical donor as a source of HSCs (HSCs). [11] [12] [13] [14] [15] [16] [17] [18] [19] The use of haploidentical donors has some advantages compared with matched unrelated donors (MUD) and cord blood units, as a donor is more widely and readily available usually within the family, abbreviating the time for stem cell collection and infusion into the recipient. 18 However, past reports of haploidentical HSCT as therapy in SAA have encountered important limitations with graft failure and risk of severe graft-versus host disease (GVHD). [11] [12] [13] [14] [15] [16] [17] [18] 20, 21 Recently, the use of post-transplant cyclophosphamide (Cy) has permitted transplantation across major HLA barriers for patients receiving BM from a haploidentical donor. [22] [23] [24] [25] [26] The use of posttransplant Cy has several advantages compared with traditional methods of ex vivo T-cell depletion, which include lower complexity and cost, and improved immune reconstitution permitting a more widespread adoption of this transplant procedure. 27 Several studies have confirmed the efficacy and safety of this approach, but most reports have focused on patients with hematologic malignancies. 28 We herein report a multicenter retrospective analysis of the outcomes of 16 patients with SAA who underwent haploidentical HSCT with a reduced-intensity conditioning and post-transplant Cy.
PATIENTS AND METHODS Patients
We retrospectively collected data on 16 patients with acquired SAA who underwent haploidentical HSCT with post-transplant Cy from July 2010 to August 2014 in four centers in Brazil. Two patients received a second transplant because of graft failure. We excluded patients with a diagnosis of constitutional aplastic anemia, patients with a previous diagnosis of other hematological disorders and those who underwent haploidentical HSCT with ex vivo T-cell depletion or other forms of T-cell depletion without the use of post-transplant Cy. This study was approved by the institutional review board of each participating institution before the initiation of data collection.
Conditioning regimen and GVHD prophylaxis
Patients were conditioned using the Hopkins regimen consisting of Cy 14.5 mg/kg (days − 6 and − 5), fludarabine 30 mg/m 2 (days − 6 to − 2) and low-dose TBI (200-600 cGy). Two patients who underwent a second haploidentical HSCT were conditioned with fludarabine 30 mg/m 2 (days − 6 to − 2) and rabbit antithymocyte globulin (ATG; dose was 2.5 mg/kg per day on days − 4 to − 2 (unique patient identifier (UPI) no.14) and days − 8 to − 6 (UPI no. 15); total dose 7.5 mg/kg per total). All patients received high-dose Cy (50 mg/kg) on days +3 and +4. Calcineurin inhibitors (CYA in 11 and tacrolimus in 7 patients) and mycophenolate mofetil (MMF; 15 mg/kg per os three times daily) were started on day +5. MMF was Haploidentical BMT in aplastic anemia I Esteves et al discontinued on day +35 if no GVHD was present, and tapering of calcineurin inhibitors started at 6-9 months.
Supportive care
All patients received anti-microbial prophylaxis for bacteria, fungal, Pneumocystis jiroveci and herpes infection according to institutional practices. Viral surveillance was performed weekly for CMV virus by quantitative PCR and/or antigenemia assay. Patients who were found to be positive for CMV by either test were treated with ganciclovir and/or foscarnet, depending on ANC at the time of diagnosis of CMV reactivation and institutional practices. Chimerism was assessed by short tandem repeat analysis in unfractionated BM cells and PB CD3+ (T cells) and CD15+ (granulocytes) cells. First, chimerism analysis was usually carried out at the time of engraftment. Full chimerism was defined as 495% donor cells and mixed chimerism as 5% to 95% donor cells. 29 The presence of donor HLAspecific Abs were assessed by solid-phase immunoassays on the Luminex platform, according to the manufacturer's instructions. Sera were tested using polled HLA Ags, HLA class I or class II phenotypes and single HLA Ags panels (One Lambda Inc., Canoga Park, CA, USA). Data were analyzed using Fusion Software (One Lambda Inc). Abs were considered positive when their normalized intensity using single-Ag bead testing was 42000 MFI (median fluorescence intensity).
Definitions
OS was estimated using the Kaplan-Meier method. OS was defined as the time from the date of transplantation until death from any cause, with patients alive at last follow-up censored. Median follow-up was estimated using the inverted Kaplan-Meier method. 30 Neutrophil engraftments were defined as the first of 3 consecutive days with an ANC ⩾ 0.5 × 10 9 /L. Date of platelet recovery was defined as the first of 7 consecutive days with a platelet count ⩾ 20 × 10 9 /L without transfusion support. Primary graft failure was defined when neutrophil counts never exceeded 0.5 × 10 9 /L at any time associated with a low/absent donor chimerism. Secondary graft failure or graft rejection was defined as neutropenia (o 0.5 × 10 9 /L) associated with complete loss of donor chimerism in patients with a prior history of engraftment. Acute and chronic GVHD were graded according to the international criteria.
RESULTS

Clinical features
Clinical features of the 16 patients at the time of HSCT are summarized in Table 1 . The majority of patients were male (68.75%), and the median age at the time of HSCT was 17 (range 5-39) years. The median age of donors was 36 (range, 26-57) years. All donors were related to the patients, most commonly parents (88%).
Fourteen patients were previously treated with rabbit ATG and CYA and two patients with steroids and CYA. Both of these patients did not receive ATG because of problems with ATG supply in the Brazilian public health-care system at the time and were treated with a Brazilian developed protocol of CYA and steroids. Among patients treated with rabbit ATG, seven (50%) were deemed refractory, five (36%) had a prior response but then evolved with disease relapse and in two cases information was missing. All patients were heavily transfused, having received more than 50 packed red blood cell transfusions. Seven patients (44%) had a history of recurrent, severe infections. No patient had significant (41000 mean fluorescence intensity) anti-HLA Abs. The predominant source of HSCs was the BM in all but three patients. Median total nucleated cells infused in the first HSCT were 8 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] days. Among the three patients who did not achieve platelet engraftment (UPI nos 1, 9 and 10), two patients (UPI nos 1 and 9) died at day +66 and +111 post transplantation, respectively, whereas UPI no. 10 was started on therapy with eltrombopag on day +112 and had an improvement in counts. Two patients had secondary graft failure (UPI nos 14 and 15). Both had received BM from their mothers, had neutrophil engraftment (on days +17 and +18) and platelet engraftment (on days +21 and +27) but developed secondary graft failure on days +40 and +35, respectively. They underwent a salvage haploidentical HSCT using a different donor (the fathers in both cases) and PB as a source of HSCs. Conditioning was with fludarabine and ATG and started on days +337 (UPI no. 14) and +295 (UPI no. 15). Dose of infused CD34+ cells was 9.56 × 10 6 CD34+ cells per kg for UPI no. 14 and 6.2 × 10 6 CD34+ cells per kg for UPI no. 15. Neutrophil engraftment occurred after 18 (UPI no. 14) and 20 days (UPI no. 15). Only one patient (UPI no. 15) had severe (o 20 × 10 9 /L) thrombocytopenia at the time of second transplant and he achieved platelet engraftment on day +18. Chimerism analysis Fourteen of 16 patients achieved complete donor chimerism at the time of engraftment, with one patient having primary graft failure and one patient achieving borderline mixed chimerism (94% donor cells; UPI no. 14). This last patient later evolved to secondary graft failure by day +40 and had to undergo salvage transplantation as mentioned above. Both patients who underwent salvage transplantation achieved complete donor chimerism at the time of neutrophil engraftment of the second transplant.
Acute and chronic GVHD Among those who engrafted (n = 15), there were three cases (20%) of grade 1-4 acute GVHD and two cases (13%) of grade 2-4 acute GVHD. Three patients (20%) developed limited chronic GVHD. One patient (UPI no. 6) developed severe (grade 4) GVHD of both skin and gastrointestinal tract on day +60, followed by limited chronic GVHD and died on day +355 from bacterial sepsis. This was the only patient who required therapy for refractory GVHD (extracorporeal photopheresis and daclizumab).
Survival
After a median follow-up period of 355 days, five patients have died with a 1-year OS of 67.1% (95% confidence interval: 36.5-86.4%) (Figure 1 ). All patients died of treatment-related mortality, and there were no relapses. Causes of death included bacterial sepsis (N = 2), pulmonary aspergillosis, viral infection and toxoplasmosis (N = 1 each). Among the seven patients who had a prior history of recurrent infections, three of them died because of pulmonary aspergillosis, viral infection and toxoplasmosis.
DISCUSSION
We have reported the results of 16 patients with relapsed/ refractory SAA who underwent haploidentical allogeneic HSCT with a reduced-intensity conditioning and post-transplant Cy.
There was a high rate of neutrophil and platelet engraftment, with 87.5% achieving complete (495%) donor chimerism at the time of engraftment. Only three patients experienced primary and/or secondary graft failure, and two of these patients were successfully salvaged with a second haploidentical HSCT. No patient had disease relapse, but our median follow-up is still relatively short. These results compare favorably with the results reported for drug therapy for patients with refractory SAA, with responses rates in the range of 30-50% for most therapeutic options. 6, 7, 9, 10 In the past, the use of haploidentical donors was limited by the incidence of severe GVHD and the need for profound ex vivo T-cell depletion, which impaired immune reconstitution and contributed to an increased risk of infections, relapse and non-relapse mortality. Post-transplant Cy is an effective strategy for GVHD prevention with reduced impairment in immune reconstitution that is observed with more profound T-cell depletion strategies previously used in haploidentical HSCT. 27, 31 In our small series, the rate of acute and chronic GVHD was low, and only one patient developed severe GVHD that needed secondary systemic therapy. The use of post transplant Cy for GVHD prophylaxis during haploidentical HSCT has been associated with relatively high rates of relapse in patients with hematologic malignancies, probably because of mitigation of the GVL effect. 28 However, for the treatment of non-malignant disorders, the occurrence of GVHD is considered unacceptable toxicity given no benefit of this immunological complication in those without a malignancy. Thus, the use of haploidentical donors could broaden the therapeutic possibilities in patients with non-malignant disorders who lack a histocompatible donor. 32 Even though we used a reduced-intensity conditioning, treatment-related mortality was the only cause of death in our series. The treatment-related mortality rate of 32.9% was relatively high compared with the rate reported (7%) in a randomized study comparing haploidentical HSCT with cord blood transplantation for hematologic malignancies. 28 However, most patients in our series had a diagnosis of SAA for several years, were heavily transfused and had a history of severe infections, which might have contributed to the mortality observed.
The use of post-transplant Cy for GVHD prophylaxis in SAA was first reported in two patients with SAA who underwent allogeneic HSCT from matched related donors, with successful engraftment and no GVHD. 33 More recently, Clay et al. 25 reported the UK experience on eight patients with SAA who underwent allogeneic PB transplantation from haploidentical donors and received posttransplant Cy with the same conditioning regimen described in our series. 25 In that series, four patients had already failed unrelated donor and/or cord blood transplants, and four had refractory acquired SAA. Another difference from our series is that all patients received PBSC grafts, which have been reported to be associated with decreased survival in patients with SAA. 34 Nevertheless, the results are similar to our series, with successful engraftment in most patients and low rates of GVHD. 25 In the UK cohort, two patients did not engraft because of anti-HLA Abs, and infection was the most common cause of death. In our series, despite the prior history of multiple transfusions, no patient had developed significant anti-HLA Abs, and this might be one of the reasons for our high rate (94%) of primary engraftment.
Another recent study from India reported on two children with SAA who underwent haploidentical HSCT with post-transplant Cy, concluding that it is a feasible therapeutic option and possibly less expensive than an MUD transplant, particularly in developing countries. 35 In our series, seven patients were either children or adolescents, confirming the efficacy of this approach for these patients.
With the increasing experience of post-transplant Cy in haploidentical HSCT in SAA, the timing and role of this procedure is likely to be considered in future algorithms. For young patients who lack a matched related donor, excellent results have been reported with the use of horse ATG as first-line therapy. 36 However, in some countries (such as Brazil), rabbit ATG is the only formulation of ATG that is commercially available, which has been associated with inferior outcomes compared with horse ATG in comparative studies as first-line therapy, resulting in a greater number patients in need of salvage therapies. 37, 38 The use of alternative donors as first salvage in younger patients with regimens including alemtuzumab is associated with excellent outcomes in retrospective studies. 39, 40 However, for those who lack a histocompatible donor (related or unrelated) and are eligible for HSCT, investigating a haploidentical source of HSCs with post-transplantation Cy in a clinical research protocol is reasonable. The salvage rate with a second course of immunosuppression in those who fail initial rabbit ATG is low at about 20-30%. 6, 41 Thus, future trials should explore the use of haploidentical allogeneic HSCT with post-transplant Cy at an earlier time point in the clinical course of younger patients with SAA who lack a histocompatible donor and are eligible for transplant before they develop anti-HLA Abs and recurrent infections that might reduce the efficacy of such approach.
